Literature DB >> 17616048

Surgical treatment of multiple intracardiac and pulmonary artery tumor implants embolic from uterine intravascular leiomyomatosis.

Raúl García Rinaldi1, José Pérez Hernández, Alma R Corbalá, Héctor R Aponte, Victor Dayán, Marta Plaza.   

Abstract

Intravenous uterine leiomyomatosis is the invasion of the para-uterine veins by bundles of benign uterine muscle. These muscle bundles can grow and extend directly to pelvic organs or embolize to the right cardiac chambers or pulmonary artery. We report a patient who presented with two large mobile atrial masses that were seen on echocardiography. She was treated by excision of a 18cm mass from the right atrium, two masses from the right ventricle and a huge mass from the pulmonary artery. The tricuspid valve that was rendered insufficient, was repaired by the creation of PTFE neo chordae. Two weeks later a massively enlarged uterus, ovaries, a paracolic and three intraluminal masses in the inferior vena cava were removed. The patient recovered well. One year after surgery she was asymptomatic and no masses are seen in her echocardiogram. The tricuspid valve was competent. Patients presenting with cardiac tumors from intravenous uterine leiomyomatosis must undergo aggressive surgical management to achieve a cure. We recommend a two stage (thoracic and abdominal) approach.

Entities:  

Mesh:

Year:  2007        PMID: 17616048

Source DB:  PubMed          Journal:  Bol Asoc Med P R        ISSN: 0004-4849


  2 in total

1.  A case of intravenous leiomyomatosis of uterine origin, extending through the inferior vena cava to right atrium.

Authors:  Hiroshi Osawa; Shigeru Hosaka; Okihiko Akashi; Hiroshi Furukawa; Koso Egi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-05-25

2.  Computerized tomography angiography in preoperative assessment of intravenous leiomyomatosis extending to inferior vena cava and heart.

Authors:  Ting Gui; Qiuhong Qian; Dongyan Cao; Jiaxin Yang; Ping Peng; Keng Shen
Journal:  BMC Cancer       Date:  2016-02-08       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.